← Back to Search

Janus Kinase (JAK) Inhibitor

INCB054707 for Vitiligo

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 25 up to week 76

Summary

This trial is testing a medication called INCB054707 to see if it can help people with nonsegmental vitiligo, a condition where the skin loses its color in patches. The study will check if the medication can safely and effectively bring back the natural color to their skin.

Eligible Conditions
  • Vitiligo

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 25 up to week 76
This trial's timeline: 3 weeks for screening, Varies for treatment, and from week 25 up to week 76 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24
Secondary study objectives
Extension Period: Number of Participants With Any TEAE
Percentage of Participants Achieving T-VASI50 at Week 24
Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

Side effects data

From 2019 Phase 2 trial • 10 Patients • NCT03569371
30%
Upper respiratory tract infection
10%
Nausea
10%
Headache
10%
Fibromyalgia
10%
Anxiety
10%
Rash
10%
Night sweats
100%
80%
60%
40%
20%
0%
Study treatment Arm
INCB054707

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: INCB054707 Dose CExperimental Treatment1 Intervention
Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
Group II: INCB054707 Dose BExperimental Treatment1 Intervention
Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
Group III: INCB054707 Dose A followed by Dose CExperimental Treatment1 Intervention
Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
Group IV: Placebo followed by INCB054707 Dose CPlacebo Group1 Intervention
Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INCB054707
2018
Completed Phase 2
~670

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
391 Previous Clinical Trials
63,664 Total Patients Enrolled
10 Trials studying Vitiligo
2,521 Patients Enrolled for Vitiligo
~38 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top